A prospective study on conversion from Sandimmune to Neoral in stable adult liver transplant recipients

Ashokkumar Jain, Mary Gadomski, John Fung

Research output: Contribution to journalArticle

Abstract

Neoral is a microemulsion formulation of cyclosporin (CyA), which has more consistent and better pharmacokinetics parameters with improved bioavailability compared to conversional formulation of Sandimmune. Sixty- four stable adults (age >18 years), who had received liver transplants (LTx) and were on Sandimmune-based immunosuppression, were converted to Neoral on milligram for milligram basis. Mean age was 52.5 ± 13.5 years and male/female distribution was 22/42. Mean interval from LTx to conversion was 109.2 ± 136 months. In 13 patients (20%) the dose of Neoral was reduced because of an increase in serum creatinine (N = 9), hyperkalemia (N = 1), headache (N = 1), peripheral parasthesia (N = 1), and a general sense of discomfort (N = 1). Interestingly, in two patients a decrease in the trough concentration was observed with the increase in liver enzymes. Both patients responded to an increase in Neoral dose. The present study suggests while the majority of the stable liver transplant patients (77%) can be safely converted to Neoral from Sandimmune on a milligram to milligram basis, they need to be carefully monitored for renal function, liver function, and trough concentration of CyA.

Original languageEnglish (US)
Pages (from-to)775-777
Number of pages3
JournalDigestive Diseases and Sciences
Volume44
Issue number4
DOIs
StatePublished - Jan 1 1999

Fingerprint

Cyclosporine
Prospective Studies
Liver
Transplants
Transplant Recipients
Hyperkalemia
Immunosuppression
Biological Availability
Headache
Creatinine
Pharmacokinetics
Kidney
Enzymes
Serum

All Science Journal Classification (ASJC) codes

  • Physiology
  • Gastroenterology

Cite this

@article{7da0c3c89901422593b6699caf3f3b6c,
title = "A prospective study on conversion from Sandimmune to Neoral in stable adult liver transplant recipients",
abstract = "Neoral is a microemulsion formulation of cyclosporin (CyA), which has more consistent and better pharmacokinetics parameters with improved bioavailability compared to conversional formulation of Sandimmune. Sixty- four stable adults (age >18 years), who had received liver transplants (LTx) and were on Sandimmune-based immunosuppression, were converted to Neoral on milligram for milligram basis. Mean age was 52.5 ± 13.5 years and male/female distribution was 22/42. Mean interval from LTx to conversion was 109.2 ± 136 months. In 13 patients (20{\%}) the dose of Neoral was reduced because of an increase in serum creatinine (N = 9), hyperkalemia (N = 1), headache (N = 1), peripheral parasthesia (N = 1), and a general sense of discomfort (N = 1). Interestingly, in two patients a decrease in the trough concentration was observed with the increase in liver enzymes. Both patients responded to an increase in Neoral dose. The present study suggests while the majority of the stable liver transplant patients (77{\%}) can be safely converted to Neoral from Sandimmune on a milligram to milligram basis, they need to be carefully monitored for renal function, liver function, and trough concentration of CyA.",
author = "Ashokkumar Jain and Mary Gadomski and John Fung",
year = "1999",
month = "1",
day = "1",
doi = "10.1023/A:1026674128059",
language = "English (US)",
volume = "44",
pages = "775--777",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Kluwer Academic Publishers-Plenum Publishers",
number = "4",

}

A prospective study on conversion from Sandimmune to Neoral in stable adult liver transplant recipients. / Jain, Ashokkumar; Gadomski, Mary; Fung, John.

In: Digestive Diseases and Sciences, Vol. 44, No. 4, 01.01.1999, p. 775-777.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A prospective study on conversion from Sandimmune to Neoral in stable adult liver transplant recipients

AU - Jain, Ashokkumar

AU - Gadomski, Mary

AU - Fung, John

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Neoral is a microemulsion formulation of cyclosporin (CyA), which has more consistent and better pharmacokinetics parameters with improved bioavailability compared to conversional formulation of Sandimmune. Sixty- four stable adults (age >18 years), who had received liver transplants (LTx) and were on Sandimmune-based immunosuppression, were converted to Neoral on milligram for milligram basis. Mean age was 52.5 ± 13.5 years and male/female distribution was 22/42. Mean interval from LTx to conversion was 109.2 ± 136 months. In 13 patients (20%) the dose of Neoral was reduced because of an increase in serum creatinine (N = 9), hyperkalemia (N = 1), headache (N = 1), peripheral parasthesia (N = 1), and a general sense of discomfort (N = 1). Interestingly, in two patients a decrease in the trough concentration was observed with the increase in liver enzymes. Both patients responded to an increase in Neoral dose. The present study suggests while the majority of the stable liver transplant patients (77%) can be safely converted to Neoral from Sandimmune on a milligram to milligram basis, they need to be carefully monitored for renal function, liver function, and trough concentration of CyA.

AB - Neoral is a microemulsion formulation of cyclosporin (CyA), which has more consistent and better pharmacokinetics parameters with improved bioavailability compared to conversional formulation of Sandimmune. Sixty- four stable adults (age >18 years), who had received liver transplants (LTx) and were on Sandimmune-based immunosuppression, were converted to Neoral on milligram for milligram basis. Mean age was 52.5 ± 13.5 years and male/female distribution was 22/42. Mean interval from LTx to conversion was 109.2 ± 136 months. In 13 patients (20%) the dose of Neoral was reduced because of an increase in serum creatinine (N = 9), hyperkalemia (N = 1), headache (N = 1), peripheral parasthesia (N = 1), and a general sense of discomfort (N = 1). Interestingly, in two patients a decrease in the trough concentration was observed with the increase in liver enzymes. Both patients responded to an increase in Neoral dose. The present study suggests while the majority of the stable liver transplant patients (77%) can be safely converted to Neoral from Sandimmune on a milligram to milligram basis, they need to be carefully monitored for renal function, liver function, and trough concentration of CyA.

UR - http://www.scopus.com/inward/record.url?scp=0032916421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032916421&partnerID=8YFLogxK

U2 - 10.1023/A:1026674128059

DO - 10.1023/A:1026674128059

M3 - Article

C2 - 10219837

AN - SCOPUS:0032916421

VL - 44

SP - 775

EP - 777

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 4

ER -